Published in Leuk Lymphoma on October 10, 2011
Quality of life after chemotherapy or hematopoietic cell transplant in follicular lymphoma: what's next? Leuk Lymphoma (2012) 0.75
The Myeloma Patient Outcome Scale is the first quality of life tool developed for clinical use and validated in patients with follicular lymphoma. Eur J Haematol (2017) 0.75
Return to work for patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation. Clin Epidemiol (2017) 0.75
Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS One (2008) 4.37
Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol (2005) 4.27
DNA methylation pattern changes upon long-term culture and aging of human mesenchymal stromal cells. Aging Cell (2009) 2.84
Aging and replicative senescence have related effects on human stem and progenitor cells. PLoS One (2009) 2.62
Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity. Blood (2004) 2.61
JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncol (2007) 2.44
The third pillar of bacterial signal transduction: classification of the extracytoplasmic function (ECF) sigma factor protein family. Mol Microbiol (2009) 2.41
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood (2011) 2.37
Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov (2013) 2.32
BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med (2012) 2.25
Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis. Int J Cardiol (2011) 2.10
Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer (2008) 2.06
Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood (2011) 1.97
Genome-wide promoter DNA methylation dynamics of human hematopoietic progenitor cells during differentiation and aging. Blood (2011) 1.92
Mesenchymal stem cell preparations--comparing apples and oranges. Stem Cell Rev (2007) 1.88
Suppression of T-cell functions by human granulocyte arginase. Blood (2006) 1.85
Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol (2013) 1.84
Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers. J Am Coll Cardiol (2012) 1.84
Identification of griseofulvin as an inhibitor of centrosomal clustering in a phenotype-based screen. Cancer Res (2007) 1.69
Retroviral vector integration occurs in preferred genomic targets of human bone marrow-repopulating cells. Blood (2002) 1.65
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood (2011) 1.65
Hematopoietic progenitor cells and cellular microenvironment: behavioral and molecular changes upon interaction. Stem Cells (2005) 1.62
Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol (2010) 1.60
High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. J Clin Oncol (2013) 1.60
Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica (2010) 1.58
Modeling of asymmetric cell division in hematopoietic stem cells--regulation of self-renewal is essential for efficient repopulation. Stem Cells Dev (2009) 1.57
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. Nat Clin Pract Oncol (2006) 1.55
Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET. Leuk Lymphoma (2007) 1.53
Different facets of aging in human mesenchymal stem cells. Tissue Eng Part B Rev (2010) 1.51
Molecular evidence for stem cell function of the slow-dividing fraction among human hematopoietic progenitor cells by genome-wide analysis. Blood (2004) 1.51
Specific age-associated DNA methylation changes in human dermal fibroblasts. PLoS One (2011) 1.51
Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol (2013) 1.49
Induction of CD4+ T-cell anergy and apoptosis by activated human B cells. Blood (2008) 1.49
Quality of life of long-term survivors with Hodgkin lymphoma after high-dose chemotherapy, autologous stem cell transplantation, and conventional chemotherapy. Leuk Lymphoma (2010) 1.49
Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies. Expert Opin Pharmacother (2012) 1.47
Molecular and secretory profiles of human mesenchymal stromal cells and their abilities to maintain primitive hematopoietic progenitors. Stem Cells (2007) 1.45
Long-term remission of paraprotein-induced immunotactoid glomerulopathy after high-dose therapy and autologous blood stem cell transplantation. Ann Hematol (2007) 1.44
Microcephalin and pericentrin regulate mitotic entry via centrosome-associated Chk1. J Cell Biol (2009) 1.41
Cellular immune responses against the cancer-testis antigen SPAN-XB in healthy donors and patients with multiple myeloma. Leuk Lymphoma (2008) 1.40
Proteins required for centrosome clustering in cancer cells. Sci Transl Med (2010) 1.35
The heterogeneity of human mesenchymal stem cell preparations--evidence from simultaneous analysis of proteomes and transcriptomes. Exp Hematol (2006) 1.35
Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst (2011) 1.34
GSK-3 mediates differentiation and activation of proinflammatory dendritic cells. Blood (2006) 1.34
DNA damage-induced accumulation of centrosomal Chk1 contributes to its checkpoint function. Cell Cycle (2007) 1.34
Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood (2011) 1.30
Co-culture with mesenchymal stromal cells increases proliferation and maintenance of haematopoietic progenitor cells. J Cell Mol Med (2009) 1.25
Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease. Blood (2007) 1.24
Impact of individual platelet lysates on isolation and growth of human mesenchymal stromal cells. Cytotherapy (2010) 1.23
Adhesion of hematopoietic progenitor cells to human mesenchymal stem cells as a model for cell-cell interaction. Exp Hematol (2007) 1.17
TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. Blood (2013) 1.16
Population dynamics of mesenchymal stromal cells during culture expansion. Cytotherapy (2011) 1.16
N-cadherin is expressed on human hematopoietic progenitor cells and mediates interaction with human mesenchymal stromal cells. Stem Cell Res (2010) 1.16
Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia. Br J Haematol (2013) 1.16
Deep sequencing-based identification of small non-coding RNAs in Streptomyces coelicolor. RNA Biol (2011) 1.15
Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma. Cancer (2010) 1.14
Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma. Exp Hematol (2006) 1.14
Replicative senescence-associated gene expression changes in mesenchymal stromal cells are similar under different culture conditions. Haematologica (2010) 1.14
Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant (2009) 1.14
Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients: results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity. Biol Blood Marrow Transplant (2011) 1.13
Role of histone deacetylase inhibitors in the treatment of cancer (Review). Int J Oncol (2004) 1.12
Aging of hematopoietic stem cells is regulated by the stem cell niche. Exp Gerontol (2008) 1.12
Increased levels of 2-hydroxyglutarate in AML patients with IDH1-R132H and IDH2-R140Q mutations. Eur J Haematol (2010) 1.11
High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. Br J Haematol (2004) 1.11
Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis. Haematologica (2008) 1.09
Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes. Exp Hematol (2009) 1.08
Poles apart: Arctic and Antarctic Octadecabacter strains share high genome plasticity and a new type of xanthorhodopsin. PLoS One (2013) 1.08
Human mesenchymal stromal cells regulate initial self-renewing divisions of hematopoietic progenitor cells by a beta1-integrin-dependent mechanism. Stem Cells (2006) 1.07
Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood (2013) 1.06
Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. Haematologica (2007) 1.06
Parenthood in long-term survivors after CHOP with or without etoposide treatment for aggressive lymphoma. Br J Haematol (2014) 1.06
Atorvastatin inhibits T cell activation through 3-hydroxy-3-methylglutaryl coenzyme A reductase without decreasing cholesterol synthesis. J Immunol (2007) 1.06
Advances in mobilization for the optimization of autologous stem cell transplantation. Leuk Lymphoma (2009) 1.05
Mycobacterium kansasii tenosynovitis in a rheumatoid arthritis patient with long-term therapeutic immunosuppression. Arthritis Rheum (2008) 1.05
Cholera toxin binds to lipid rafts but has a limited specificity for ganglioside GM1. Immunol Cell Biol (2007) 1.04
Evaluation of mineralized collagen and alpha-tricalcium phosphate as scaffolds for tissue engineering of bone using human mesenchymal stem cells. Cells Tissues Organs (2004) 1.03
Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia. J Clin Oncol (2013) 1.03
Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma. Clin Cancer Res (2007) 1.03
Chromosomal instability correlates with poor outcome in patients with myelodysplastic syndromes irrespectively of the cytogenetic risk group. J Cell Mol Med (2009) 1.03
Highly efficient expansion of human CD4+CD25+ regulatory T cells for cellular immunotherapy in patients with graft-versus-host disease. J Immunother (2006) 1.03
Chk1-dependent regulation of Cdc25B functions to coordinate mitotic events. Cell Cycle (2006) 1.02
Primitive human hematopoietic cells give rise to differentially specified daughter cells upon their initial cell division. Blood (2005) 1.02
Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma. J Immunol (2011) 1.02